Clinical Trial Update: Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing isolated pelvic perfusion with TNF-α and melphalan versus standard treatment in non-resectable, recurrent gynecologic or digestive pelvi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive Cancer
• Gynecologic Cancer

Drugs mentioned

• Melphalan (Melphalan)
• TNF-α (tumor necrosis factor alpha)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Gynaecologic or Digestive Pelvic Cancer | Phase 3 | Status: COMPLETED